Home › Funds › Palo Alto Investors LP › TVTX

Palo Alto Investors LP position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Palo Alto Investors LP reported holding 158,946 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$9.4M, representing 1.39% of its reported portfolio and ranking #21 among its reported holdings. Palo Alto Investors LP has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)158.95K sh
Reported value held$9.36M
Portfolio Weight1.39%
First reportedQ3 2023
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Palo Alto Investors LP's TVTX position evolved

Palo Alto Investors LP first disclosed a stake in TVTX in Q3 2023 at 166,069 shares (US$1.5M). The position peaked in Q2 2026 at 167,525 shares, worth US$9.5M. Across 13 filings, Palo Alto Investors LP increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 158,946 shares valued at US$9.4M — a reduction of -8,579 shares quarter over quarter.. Notable position changes include a 33% trim in Q4 2023 (shares fell 14% over the following quarter), a 108% increase in Q1 2026 (shares rose 91% over the following quarter), a 27% trim in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 166.07K $1.48M New
Q4 2023 110.72K $995.36K Reduce
Q1 2024 110.72K $853.64K Hold
Q2 2024 110.72K $910.11K Hold
Q3 2024 110.72K $1.55M Hold
Q4 2024 110.72K $1.93M Hold
Q1 2025 110.72K $1.98M Hold
Q2 2025 110.72K $1.64M Hold
Q3 2025 110.72K $2.65M Hold
Q4 2025 110.72K $4.23M Hold
Q1 2026 230.45K $6.85M Add
Q2 2026 167.53K $9.52M Reduce
Q3 2026 158.95K $9.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$208.6M), Rock Springs Capital Management LP (US$129.8M), Kynam Capital Management, LP (US$117.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Palo Alto Investors LP held TVTX?

Palo Alto Investors LP has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Palo Alto Investors LP's current position in TVTX?

As of Q3 2026, Palo Alto Investors LP holds 158.95K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $9.36M, representing 1.39% of its reported portfolio and ranking #21.

Has Palo Alto Investors LP been buying or selling TVTX?

In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in TVTX. The position peaked in Q2 2026 at 167.53K shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.